Vipin K. Garg, Ph.D.President and Chief Executive Officer
Dr. Garg joins Altimmune with over three decades of experience in the biotechnology and pharmaceutical industries. He has a proven track record of building and managing both private and publicly traded companies. Before joining Altimmune, he served as President and CEO of Neos Therapeutics (Nasdaq: NEOS), where he built a commercial-stage biopharmaceutical company launching three branded therapeutic products including Adzenys XR- ODTTM and Cotempla XR-ODTTM the first ever XR-ODTTM medications for the treatment of ADHD. Prior to Neos, he served as president and CEO of Tranzyme Pharma where he progressed a discovery-stage, emerging biotech company to a Nasdaq-listed clinical-stage, drug development company. Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of Apex Bioscence, Inc. (acquired by Curacyte AGof Munich, Germany), and held senior management positions at DNX Bio-Therapeutics, Inc. until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Sumitomo Dainippon Pharma), and Bio-Response Inc.(acquired by Baxter Healthcare Corporation). Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia, and his M.S. from IARI Nuclear Research Laboratory, New Delhi, India in 1978.
Will BrownChief Financial Officer
Mr. Will Brown was appointed Acting Chief Financial Officer and Principal Accounting Officer in May 2018 after having consulted with the company since February 2018. Mr. Brown has been a consultant to several private and public companies in a variety of accounting and tax matters both independently and as the managing partner of Redmont CPAs. Prior to his consulting role, he was an audit manager at PwC and a Division Controller at Rheem, a multinational manufacturing company. Mr. Brown is a CPA and earned both his Bachelor of Science and Master of Business Administration from Auburn University at Montgomery.
Scot Roberts, Ph.D.Chief Scientific Officer
Dr. Roberts joined us in December 2012 and has nearly 20 years of senior technical leadership experience, most recently as Chief Scientific Officer at ImQuest BioSciences, Inc., where he was responsible for managing scientific operations as well as business development opportunities in cancer and antivirals. Dr. Roberts held key positions at Wellstat Biologics Corporation from August 1996 until October 2010, including Director of Research and Development where he was responsible for a portfolio of biologic candidates in oncology including a clinical stage asset. He also led bioassay development efforts for the company and assumed leadership roles in upstream process development and animal pharmacology while at Wellstat. Dr. Roberts has significant experience in both small molecule and biologics drug development with a focus on viral vectors and antiviral therapies. Dr. Roberts completed a post doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and has numerous patents and publications in peer-reviewed journals, and has been an invited speaker and Chair at numerous international conferences. Dr. Roberts received his Ph.D. from the Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences.
Bertrand Georges, Ph.D.Chief Technology Officer
Dr. Georges has 17 years expertise in the field of molecular & cellular immunology and T cell vaccine development. He was co-founder and Chief Technology Officer of Immune Targeting Systems (ITS) Limited from 2004 until its acquisition by Altimmune in March 2015. Prior to ITS, Dr. Georges held the position of head of immunology at SEDAC-Therapeutics from 1999 until 2003. Dr. Georges has significant experience in product formulation and manufacturing, preclinical and early clinical development with a focus on peptide-based vaccines. Dr. Georges has a special interest in designing vaccines against infectious diseases and cancer and has developed T cell epitope identification methodologies combining in silico, in vitro and in vivo approaches. He received his Ph.D. in Molecular Immunology from the Pasteur Institute and is the co-author of 20 publications and co-inventor of 13 patent families.
José OchoaChief Business Officer
José joined Altimmune as Chief Business Officer in July of 2018. A biotech executive with over 25 years’ experience structuring, negotiating and completing complex and accretive transactions including joint ventures, partnerships, mergers, acquisitions, debt financings, licensing and restructurings in a broad range of industries, he was most recently with IDT Biologika Corporation, where he served as Chief Business Officer & Head of Animal Health Americas. Prior to IDT, José was at Emergent BioSolutions and its predecessor BioPort Corporation for over a decade where he held a variety of position of increasing responsibility and led mergers & acquisitions, partnering, joint ventures, licensing, corporate strategy and alliance management functions. Mr. Ochoa also served as General Counsel at BioPort and East West Resources Corporation, counsel to BellSouth International (now AT&T) and the law firms of Luce Forward Hamilton & Scripps in San Diego, California and Arent Fox in Washington, D.C., Mr. Ochoa received his juris doctor from the University of Virginia, and his bachelor of arts, with distinction, from the University of Virginia.
Joe Theis, JDOutside General Counsel
Joe is Outside General Counsel and a partner in Goodwin Procter LLP's Technology Companies and Capital Markets practices. He concentrates in general corporate and securities law and has significant experience in capital markets transactions, mergers and acquisitions, venture capital financings, SEC compliance and corporate governance. Joe represents public and private emerging growth technology companies as well as venture capital funds and investment banks focusing on technology companies. He has experience advising companies through every stage of the corporate life cycle – from initial financing through successful initial public offering or acquisition. Listed in Chambers USA: America's Leading Lawyers for Business since 2014, Joe captures attention for his capital markets practice, often featuring significant IPOs. He is viewed as a "very effective counselor to his clients," and has been praised for his "business focus, responsiveness and knowledge of the market."